Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 21, 2017. The document serves as a transaction notification regarding dealings by a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Exercise of share options and subsequent sale |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 4,820 shares |
| Exercise Price | £11.47 per share |
| Sale Price | £16.93 per share |
| Transaction Date | June 20, 2017 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a routine equity transaction by a senior executive.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports the exercise of options granted on February 19, 2008, under the GlaxoSmithKline 2001 Share Option Plan - UK Unapproved Trust, followed by the immediate sale of those shares on the London Stock Exchange.
Key Facts for Investor Verification
- Executive Action: Mrs. V A Whyte, Company Secretary, exercised options for 4,820 shares and sold them on the same day.
- Transaction Economics: The shares were exercised at £11.47 and sold at £16.93, indicating a realized gain on the transaction.
- Scope Limitation: This filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F or other earnings releases for financial metrics.